Metformin Hydrochloride

Metformin Hydrochloride, the active ingredient in this product, is a biguanide presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus and is also employed off‑label for polycystic ovary syndrome in adult patients, helping to improve glycaemic control and insulin sensitivity.

GNH USA supplies Metformin Hydrochloride as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels across the EU and other global markets and adhering to stringent quality standards.

Metformin Hydrochloride is used in the management of metabolic disorders that affect glucose regulation. - Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose. - Polycystic ovary syndrome: reduces insulin resistance and may help restore ovulatory cycles in affected women. - Prediabetes: delays progression to overt diabetes by improving insulin sensitivity.

Metformin Hydrochloride may be associated with several adverse reactions, ranging from mild gastrointestinal symptoms to rare but serious conditions.

Common Side Effects: - Nausea: mild to moderate nausea, especially at treatment initiation. - Diarrhea: loose stools that may improve with continued therapy. - Abdominal discomfort: cramping or bloating reported by some patients. - Metallic taste: transient metallic sensation in the mouth. - Loss of appetite: reduced desire to eat, often transient.

Serious or Rare Side Effects: - Lactic acidosis: a rare metabolic emergency characterized by elevated blood lactate. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Vitamin B12 deficiency: long‑term use may lead to decreased B12 levels requiring monitoring. - Hepatotoxicity: rare liver injury presenting with jaundice or elevated enzymes.

When prescribing Metformin Hydrochloride, clinicians should consider several precautionary measures to minimize risk and ensure optimal therapy. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic impairment: avoid use in patients with significant liver disease due to lactic acidosis risk. - Cardiovascular status: monitor for heart failure, as reduced perfusion may increase lactic acidosis risk. - Concomitant alcohol: limit intake because alcohol can potentiate lactic acidosis. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metformin Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, heightening toxicity. - Certain antiretrovirals (e.g., didanosine): increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance, requiring dose adjustment. - Beta‑blockers: can mask hypoglycaemia symptoms when combined with insulin. - ACE inhibitors or ARBs: monitor renal function as combined effect may reduce clearance. - Thyroid hormones: may enhance glucose‑lowering effect, necessitating glucose monitoring.